Alzheimer's Research & Therapy | Volume 3 Issue 2

Submit a manuscript Register Contact us Follow us on Twitter

Explore journal

Advertisement

Articles

cover

	Volume 3 Issue 2
	Comment
	Commentary Selectivity to amyloid-β precursor protein cleavage provides hope against Alzheimer's Taisuke Tomita, Philip C Wong Alzheimer's Research & Therapy 2011, 3:7 (11 March 2011) Abstract \| Full text \| PDF \| PubMed
	Viewpoint Requiring an amyloid-β_1-42biomarker may improve the efficiency of a study, and simulations may help in planning studies Suzanne B Hendrix Alzheimer's Research & Therapy 2011, 3:10 (28 March 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	Review
	Review PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease Michael J Pontecorvo, Mark A Mintun Alzheimer's Research & Therapy 2011, 3:11 (29 March 2011) Abstract \| Full text \| PDF \| PubMed
	Review Investigational drugs for the treatment of AD: what can we learn from negative trials? Sandra A Jacobson, Marwan N Sabbagh Alzheimer's Research & Therapy 2011, 3:14 (15 April 2011) Abstract \| Full text \| PDF \| PubMed
	Review What can we learn from study of Alzheimer's disease in patients with Down syndrome for early-onset Alzheimer's disease in the general population? Robyn A Wallace, Arthur J Dalton Alzheimer's Research & Therapy 2011, 3:13 (19 April 2011) Abstract \| Full text \| PDF \| PubMed
	Research
	Research Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice Bin Li, Maria E Gonzalez-Toledo, Chun-Shu Piao, Allen Gu, Roger E Kelley, Li-Ru Zhao Alzheimer's Research & Therapy 2011, 3:8 (15 March 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stem cell factor and granulocyte-colony stimulating factor limit beta-amyloid accumulation in a mouse model suggesting treatment with hematopoeitic growth factors may offer a new therapeutic approach for Alzheimer’s disease.
	Research For debate: substituting placebo controls in long-term Alzheimer's prevention trials René Spiegel, Manfred Berres, André R Miserez, Andreas U Monsch, the Alzheimer's Disease Neuroimaging Initiative Alzheimer's Research & Therapy 2011, 3:9 (21 March 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A novel clinical study design, which uses mathematical models to forecast outcomes, may complement forthcoming long-term, randomized Alzheimer’s disease drug studies and remove the need for placebo controls.
	Research CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques Eloise H Kok, Teemu Luoto, Satu Haikonen, Sirkka Goebeler, Hannu Haapasalo, Pekka J Karhunen Alzheimer's Research & Therapy 2011, 3:12 (5 April 2011) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary CLU, CR1 and PICALM genes are not strongly related to senile plaque prevalence, or at all to neurofibrillary tangles, and most likely do not affect the development of these Alzheimer’s disease (AD) lesions.
	Research Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy, Olivier Hermine Alzheimer's Research & Therapy 2011, 3:16 (19 April 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary The selective oral tyrosine kinase inhibitor, masitinib, administered as an adjunctive therapy, slows the rate of cognitive decline in Alzheimer’s disease (AD) although further studies are needed to investigate its efficacy and safety.